UC Davis Health’s IFM Fund Backs Delix Therapeutics in First Investment
UC Davis Health Ventures, part of the Innovation and Economic Development Office (IEDO) at the University of California, Davis, today announced the first investment from its Investing in the Future of Medicine (IFM) Fund, backing Delix Therapeutics. Delix, a UC Davis spinout, is developing non-hallucinogenic neuroplastogens for major depressive disorder (MDD) and other serious neuropsychiatric and neurodegenerative conditions. […]









